01.27.15
SGS Life Science Services has completed the expansion of its facility in West Chester, PA, adding new instruments for advanced analytical techniques that have been installed and validated to support the structural analysis of proteins.
Traditionally, the West Chester facility has offered primary protein and glycosylation structural analysis, in addition to Circular Dichroism, used to determine secondary protein structure. The recent expansion includes Analytical Ultra Centrifugation (AUC) for determining protein aggregation, size exclusion chromatography with multi-angle laser light scattering for establishing molecular weight profiles, and Fourier transform infrared spectroscopy (FTIR) to examine protein secondary structure.
The facility now mirrors the company’s capabilities at its site in Wokingham, UK, including investigation of lot-to-lot variations, biosimilar comparability, and shipment excursion studies to monitor the stability and sensitivity of biological molecules under various storage conditions.
“This investment will allow SGS to keep up with our clients’ ever growing pipelines for biological therapeutics, and also for the numerous biosimilars under development,” said Mark Rogers, Senior VP, Life Science Services, SGS North America. “We have seen the demand for these services increase and, with the impending changes to legislation for marketing biosimilars, we envisage that the need for these analyses, in order to demonstrate similarity, will continue to grow.”
The investment follows increased analytical capabilities at its facilities in France, China, UK, India and the U.S.
Traditionally, the West Chester facility has offered primary protein and glycosylation structural analysis, in addition to Circular Dichroism, used to determine secondary protein structure. The recent expansion includes Analytical Ultra Centrifugation (AUC) for determining protein aggregation, size exclusion chromatography with multi-angle laser light scattering for establishing molecular weight profiles, and Fourier transform infrared spectroscopy (FTIR) to examine protein secondary structure.
The facility now mirrors the company’s capabilities at its site in Wokingham, UK, including investigation of lot-to-lot variations, biosimilar comparability, and shipment excursion studies to monitor the stability and sensitivity of biological molecules under various storage conditions.
“This investment will allow SGS to keep up with our clients’ ever growing pipelines for biological therapeutics, and also for the numerous biosimilars under development,” said Mark Rogers, Senior VP, Life Science Services, SGS North America. “We have seen the demand for these services increase and, with the impending changes to legislation for marketing biosimilars, we envisage that the need for these analyses, in order to demonstrate similarity, will continue to grow.”
The investment follows increased analytical capabilities at its facilities in France, China, UK, India and the U.S.